Clinical Research Directory
Browse clinical research sites, groups, and studies.
Trial Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant RT in Head & Neck Malignancies
Sponsor: All India Institute of Medical Sciences
Summary
Hypo-fractionated radiotherapy reduces the OTT (overall treatment time) which may in turn reduce rapid accelerated repopulation of clonogenic cells during waiting period after surgery. If this holds true, there is a potential to achieve better loco-regional control in with PORT for HNSCC. There is a strong radiobiological and economic rationale for delivery hypo-fractionated radiotherapy in HNSCC. The HYPCON III trial will be aimed to reduce the number of fractions by 50% (30 fr to 15 fr)
Official title: The HYPCON 3 Trial A Phase II/III Randomized Study Evaluating Hypo-fractionated Accelerated Versus Conventional Fractionated Adjuvant Radiation Therapy in Head and Neck Malignancies
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
369
Start Date
2026-02-10
Completion Date
2028-12-30
Last Updated
2026-05-07
Healthy Volunteers
No
Interventions
Standard conventionally fractionated PORT
60Gy in 30 fractions over 6 weeks (5 fractions per week)
hypo-fractionated PORT
4Gy in 15 fractions over 3 weeks (5 fractions per week)
Locations (1)
Dr. Aman Sharma, Associate Professor, Radiation Oncology, NCI, AIIMS
Jhajjar, Haryana, India